The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 18, 2014
Filed:
Aug. 25, 2006
Silvio Traversa, Palazzo Canavese, IT;
Raffaella Bagnod, Bollengo, IT;
Domenico Barone, Turin, IT;
Luisa Bertarione Rava Rossa, Pavon Canavese, IT;
Silvano Fumero, Ivrea, IT;
Valentina Mainero, Ivrea, IT;
Alessandra Marconi, Reggio Emilia, IT;
Cecilia Oderda, Vésenaz, CH;
Carlo Pincelli, Sassuolo, IT;
Chiara Lorenzetto, Villafranca Piemonte, IT;
Luca Beccaria, Ivrea, IT;
Silvio Traversa, Palazzo Canavese, IT;
Raffaella Bagnod, Bollengo, IT;
Domenico Barone, Turin, IT;
Luisa Bertarione Rava Rossa, Pavon Canavese, IT;
Silvano Fumero, Ivrea, IT;
Valentina Mainero, Ivrea, IT;
Alessandra Marconi, Reggio Emilia, IT;
Cecilia Oderda, Vésenaz, CH;
Carlo Pincelli, Sassuolo, IT;
Chiara Lorenzetto, Villafranca Piemonte, IT;
Luca Beccaria, Ivrea, IT;
Creabilis Therapeutics S.p.A., Colleretto Giacosa, IT;
Abstract
The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. The invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of a) neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system; b) dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis; and c) NGF-related pain. More specifically, the present invention relates to a polymer conjugate of K-252a and derivatives thereof, wherein the polymer is polyethylene glycol or methoxy-polyethylene glycol formula (I).